Immuneering Announces Participation in November Investor Conferences
November 03 2022 - 6:50AM
Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company
that aims to create medicines for all patients with solid tumors
driven by RAS mutations and other MAPK pathway activation events,
today announced that management will participate in three November
investor conferences to share commentary around the Company’s
pipeline, platform, and business strategy. Presenting will be Ben
Zeskind, Ph.D., Co-Founder, and Chief Executive Officer and Brett
Hall, Ph.D., Chief Scientific Officer.
Immuneering will participate in the following conferences:
Jefferies London Healthcare Conference, London,
EnglandFormat: Fireside ChatDate: November 15, 2022Time:
12:55-1:25 pm CET
34 Annual Piper Sandler Healthcare Conference, New York,
NYFormat: Formal PresentationDate: November 29, 2022Time:
10:30-10:55 am ET
5th Annual Evercore ISI HealthCONx Conference,
VirtualFormat: Fireside ChatDate: December 1, 2022Time:
9:40-10:00 am ET
The audio portions of the presentations will be webcast live and
archived for 30 days in the Investor Relations section of
Immuneering’s website at Events & Presentations | Immuneering
Corporation.
About Immuneering CorporationImmuneering aims
to create medicines for all patients with solid tumors driven by
RAS mutations and other MAPK pathway activation events. Immuneering
has more than a decade of experience applying translational
bioinformatics to generate insights into drug mechanism of action
and patient treatment response. Building on this experience,
Immuneering's disease-agnostic discovery platform enables the
company to create product candidates based on 1) biological
insights that are both counterintuitive and deeply rooted in data,
and 2) novel chemistry. Immuneering is evaluating its lead product
candidate, IMM-1-104, in a Phase 1/2a clinical trial in advanced
solid tumors with RAS mutations (NCT05585320). IMM-1-104 aims to
achieve pan-RAS activity that selectively impacts cancer cells to a
greater extent than healthy cells. IMM-1-104 is designed to be a
highly selective third generation dual MEK inhibitor that modulates
the signaling dynamics of the MAPK pathway by driving deep cyclic
inhibition that deprives tumor cells of the sustained proliferative
signaling required for rapid growth, while providing a cadenced,
normalizing level of signaling designed to spare healthy cells.
IMM-1-104 is translationally guided by Immuneering's proprietary,
human-aligned 3D tumor modeling platform combined with patient
aligned bioinformatics. In addition to IMM-1-104, Immuneering is
currently evaluating IMM-6-415 in IND-enabling studies. The earlier
Immuneering drug discovery pipeline includes five additional
oncology programs as well as two neuroscience programs.
Forward-Looking StatementsThis press release
includes certain disclosures that contain "forward-looking
statements," including, without limitation, statements regarding
Immuneering’s expectations regarding the treatment potential of
IMM-1-104 and IMM-6-415, the timing of commencement and enrollment
of the Phase 1/2a clinical trial for IMM-1-104, the design,
enrollment criteria and conduct of the Phase 1/2a clinical trial,
the timing of submission of the IND and commencement of clinical
trials for IMM-6-415 and Immuneering’s ability to advance its
pipeline and further diversify its portfolio and make progress
towards its longstanding goal of creating better medicines for
cancer patients. Forward-looking statements are based on
Immuneering’s current expectations and are subject to inherent
uncertainties, risks and assumptions that are difficult to predict.
Factors that could cause actual results to differ include, but are
not limited to, the risks inherent in oncology and neuroscience
drug development, including target discovery, target validation,
lead compound identification, lead compound optimization,
preclinical studies and clinical trials. These and other risks and
uncertainties are described more fully in the section titled "Risk
Factors" in Immuneering’s most recent Form 10-Q filed with the U.S.
Securities and Exchange Commission. Forward-looking statements
contained in this announcement are made as of this date, and
Immuneering undertakes no duty to update such information except as
required under applicable law.
Corporate Contact:Rebecca Kusko,
Ph.D.Immuneering Corporation617-500-8080rkusko@immuneering.com
Investor Contact:Susan A. NoonanS.A. Noonan
Communications917-513-5303susan@sanoonan.com
Immuneering (NASDAQ:IMRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Immuneering (NASDAQ:IMRX)
Historical Stock Chart
From Jul 2023 to Jul 2024